Insider Selling: Coherus Biosciences Inc (NASDAQ:CHRS) COO Sells 2,500 Shares of Stock

Coherus Biosciences Inc (NASDAQ:CHRS) COO Vincent R. Anicetti sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $19.00, for a total transaction of $47,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Vincent R. Anicetti also recently made the following trade(s):

  • On Monday, July 15th, Vincent R. Anicetti sold 2,500 shares of Coherus Biosciences stock. The shares were sold at an average price of $19.20, for a total transaction of $48,000.00.

Shares of CHRS stock traded up $0.37 during midday trading on Friday, reaching $18.88. 690,635 shares of the company were exchanged, compared to its average volume of 932,941. Coherus Biosciences Inc has a 12 month low of $8.32 and a 12 month high of $23.43. The company has a market cap of $1.29 billion, a P/E ratio of -5.86 and a beta of 3.10. The company’s 50 day moving average price is $19.37 and its two-hundred day moving average price is $16.90.



Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.40. The company had revenue of $83.43 million for the quarter, compared to the consensus estimate of $81.05 million. Equities research analysts predict that Coherus Biosciences Inc will post 0.89 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its holdings in shares of Coherus Biosciences by 4.1% in the fourth quarter. Bank of New York Mellon Corp now owns 222,542 shares of the biotechnology company’s stock valued at $2,013,000 after buying an additional 8,766 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Coherus Biosciences by 150.7% in the fourth quarter. Bank of America Corp DE now owns 126,325 shares of the biotechnology company’s stock valued at $1,143,000 after buying an additional 75,928 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Coherus Biosciences by 12.3% in the fourth quarter. Legal & General Group Plc now owns 9,095 shares of the biotechnology company’s stock valued at $82,000 after buying an additional 998 shares during the last quarter. Ellis Investment Partners LLC purchased a new stake in shares of Coherus Biosciences in the first quarter valued at about $155,000. Finally, Boston Advisors LLC raised its holdings in shares of Coherus Biosciences by 79.0% in the first quarter. Boston Advisors LLC now owns 59,165 shares of the biotechnology company’s stock valued at $807,000 after buying an additional 26,105 shares during the last quarter. Institutional investors own 99.53% of the company’s stock.

Several analysts recently weighed in on CHRS shares. Mizuho started coverage on shares of Coherus Biosciences in a research report on Tuesday. They issued a “buy” rating and a $43.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective (up from $28.00) on shares of Coherus Biosciences in a research report on Friday, August 2nd. Maxim Group reiterated a “buy” rating and issued a $27.00 price objective (up from $25.00) on shares of Coherus Biosciences in a research report on Friday, August 2nd. BidaskClub downgraded shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a research report on Friday, July 19th. Finally, Barclays set a $31.00 price objective on shares of Coherus Biosciences and gave the company a “buy” rating in a research report on Monday. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $31.38.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Featured Article: What is an inverted yield curve?

Insider Buying and Selling by Quarter for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.